


AMENDMENT

IN THE SPECIFICATION:

Kindly amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

Page 1, 1st paragraph, beginning on line 2:

 This application is a divisional application of U.S. application Serial No. 09/347,594 filed July 1, 1999, now U.S. Patent No. 6,2127,883, issued April 17, 2001, which claims priority from French application No. 98 08777, filed July 6, 1998. Reference is also made to U.S. application Serial No. 09/161,092, filed September 25, 1998 as a continuation-in-part of U.S. application Serial No. 09/082,558, filed May 21, 1998, claiming priority from French applications Nos. 97 12382, 98 00873 and 98 03707, filed October 3, 1997, January 22, 1998 and March 20, 1998, respectively. Reference is further made to the U.S. applications of Audonnet et al. and Bublot et al., Serial Nos. 60/138,352 and 60/138,478, respectively, both filed June 10, 1999 ("DNA VACCINE-PCV", and "PORCINE CIRCOVIRUS RECOMBINANT POXVIRUS VACCINE", respectively; attorney dockets 454313-2335 and TH-015, respectively). Reference is additionally made to each of the documents cited in the text and in the record or prosecution of each of the aforementioned U.S. and French applications, including without limitation WO 98/03658, published January 29, 1998 from PCT/FR97/01313, filed July 15, 1997 and designating the U.S. and claiming priority from French application 96 09338, filed July 19, 1996 (the U.S. continuation-in-part of PCT/FR97/01313 being U.S. application Serial No. 09/232,468, filed January 15, 1999). Each of the aforementioned U.S., PCT and French applications (including parenthetically), and each document cited in the text and the record or prosecution of each of the aforementioned U.S., PCT and French applications (including parenthetically), is hereby incorporated herein by reference; and, technology in each of the aforementioned U.S., PCT and French applications (including parenthetically), and each document cited in the text and the record or prosecution of each of the aforementioned U.S., PCT and French applications (including parenthetically) can be used in the practice of this invention.

Kindly delete the second abstract (located on the page following the first abstract which appears on page 37).